PL2917229T3 - Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania - Google Patents

Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania

Info

Publication number
PL2917229T3
PL2917229T3 PL13791794T PL13791794T PL2917229T3 PL 2917229 T3 PL2917229 T3 PL 2917229T3 PL 13791794 T PL13791794 T PL 13791794T PL 13791794 T PL13791794 T PL 13791794T PL 2917229 T3 PL2917229 T3 PL 2917229T3
Authority
PL
Poland
Prior art keywords
hla
antibodies
fragments
alpha
protein
Prior art date
Application number
PL13791794T
Other languages
English (en)
Inventor
Maria de las Nieves Loustau
Julien Caumartin
Pierre Langlade-Demoyen
Original Assignee
Invectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47221996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2917229(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Invectys filed Critical Invectys
Publication of PL2917229T3 publication Critical patent/PL2917229T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL13791794T 2012-11-12 2013-11-12 Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania PL2917229T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306398.4A EP2730588A1 (en) 2012-11-12 2012-11-12 Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
EP13791794.4A EP2917229B1 (en) 2012-11-12 2013-11-12 Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof
PCT/EP2013/073648 WO2014072534A1 (en) 2012-11-12 2013-11-12 Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof.

Publications (1)

Publication Number Publication Date
PL2917229T3 true PL2917229T3 (pl) 2021-01-11

Family

ID=47221996

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13791794T PL2917229T3 (pl) 2012-11-12 2013-11-12 Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania

Country Status (7)

Country Link
US (1) US10005845B2 (pl)
EP (2) EP2730588A1 (pl)
CA (1) CA2891184A1 (pl)
DK (1) DK2917229T3 (pl)
ES (1) ES2786049T3 (pl)
PL (1) PL2917229T3 (pl)
WO (1) WO2014072534A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
CN107533051B (zh) * 2015-03-27 2020-11-13 南加利福尼亚大学 Hla-g作为car t细胞免疫疗法的新靶标
JP2018518152A (ja) 2015-03-27 2018-07-12 ユニバーシティ オブ サザン カリフォルニア 充実性腫瘍を処置するためのｌｈｒに指向されたｃａｒ ｔ細胞治療
CN109563169B (zh) * 2016-06-03 2022-07-01 英韦克泰斯公司 抗hla-g特异性抗体
AU2017301705A1 (en) * 2016-07-26 2019-01-24 North Carolina State University Vector-mediated immune tolerance in the eye
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CA3063959A1 (en) * 2017-05-23 2018-11-29 Valentin BRUTTEL Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
EP3434688A1 (en) * 2017-07-24 2019-01-30 Commissariat à l'Energie Atomique et aux Energies Alternatives Hla-g transcripts and isoforms and their uses
WO2019177054A1 (ja) * 2018-03-13 2019-09-19 国立大学法人北海道大学 腫瘍予防又は治療剤、ｐｄ－ｌ１抑制剤、腫瘍予防又は治療剤のスクリーニング方法及びｐｄ－ｌ１抑制剤のスクリーニング方法
AR114789A1 (es) * 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
US11492387B2 (en) * 2018-05-09 2022-11-08 Tianjin Dongya Biological Technology Co., Ltd. Broad spectrum vaccine, preparing method and application thereof
CN113056483A (zh) 2018-07-09 2021-06-29 戊瑞治疗有限公司 结合到ilt4的抗体
MA53381A (fr) 2018-07-24 2021-06-02 Amgen Inc Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
WO2020043899A1 (en) * 2018-08-31 2020-03-05 Invectys Chimeric antigen receptors against multiple hla-g isoforms
WO2020069133A1 (en) 2018-09-27 2020-04-02 Tizona Therapeutics Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
CN113045656B (zh) * 2020-07-27 2022-03-08 台州恩泽医疗中心(集团) 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
US20220306747A1 (en) * 2021-03-24 2022-09-29 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
GB202111905D0 (en) * 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023184734A1 (zh) * 2022-03-31 2023-10-05 台州恩泽医疗中心(集团) 一种抗hla-g1，-g2，-g5及hla-g6异构体分子的单克隆抗体及其用途
CN115819583A (zh) * 2022-03-31 2023-03-21 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042128A1 (fr) * 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
EP1328290A2 (en) 2000-09-15 2003-07-23 University of Kansas Medical Center Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
US9175064B2 (en) 2003-11-04 2015-11-03 Shuji Miyagawa HLA-E chimeric molecule
CN1312182C (zh) 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
WO2009100135A2 (en) * 2008-02-04 2009-08-13 Medical College Georgia Research Institute, Inc. Hla-g compositions and methods of use thereof
RU2605318C2 (ru) * 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
CA2764860C (en) 2009-06-25 2018-04-24 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
CN101967191A (zh) 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
CN109563169B (zh) 2016-06-03 2022-07-01 英韦克泰斯公司 抗hla-g特异性抗体

Also Published As

Publication number Publication date
US10005845B2 (en) 2018-06-26
CA2891184A1 (en) 2014-05-15
EP2917229A1 (en) 2015-09-16
EP2730588A1 (en) 2014-05-14
ES2786049T3 (es) 2020-10-08
US20160272724A1 (en) 2016-09-22
DK2917229T3 (da) 2020-04-06
WO2014072534A1 (en) 2014-05-15
EP2917229B1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
PL2917229T3 (pl) Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania
ZA201407927B (en) Anti-egfr antibodies and uses thereof
HK1212256A1 (en) Anti-mcam antibodies and associated methods of use -mcam
HK1205517A1 (en) Anti sez6 antibodies and methods of use sez6
ZA201500887B (en) Human anti-cd27 antibodies, methods and uses
HK1209373A1 (en) Anti-ly6e antibodies and immunoconjugates and methods of use ly6e
HK1231485A1 (zh) 抗體及其使用方法
SI3912642T1 (sl) Modificirano protitelo, konjugat protitelesa in postopek za pripravo le-teh
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
IL238223B (en) Nanoparticle mhc antigen complex, method for preparation and composition containing it
HK1209432A1 (en) Anti-jagged antibodies and methods of use
ZA201407309B (en) Antigens and antigen combinations
GB201207383D0 (en) Antigens and antigen combinations
GB201207385D0 (en) Antigens and antigen combinations